Cancer Vaccines Market Growth, Size, Trends, Demand, Revenue, Competition and Future Outlook
Global Cancer Vaccines Market Size- By Technology, By Type, By Indication, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2032
| Published: Dec-2022 | Report ID: HLCA2233 | Pages: 1 - 242 | Formats*: |
| Category : Healthcare | |||
Cancer Vaccines Market Introduction and Overview
According to SPER Market Research, the Global Cancer Vaccines Market is estimated to reach USD 20.09 billion by 2032 with a CAGR of 12.82%.
The report includes an in-depth analysis of the Global Cancer Vaccines market, including market size and trends, product mix, distribution channels, and supplier analysis. Vaccines are medications that boost the body's immune system in order to defend it from outside intruders. Cancer vaccines are pharmaceuticals that modify biological responses. An immune system that has been activated eliminates foreign objects. The idea behind vaccines is that they help the body memorize foreign invaders so that they won't cause illness when they return. Biological response modifiers include cancer vaccinations. To fight disease, these modifiers work by triggering the immune system. Anxia Biosciences started the Phase Ib clinical study for its vaccine to prevent breast cancer in October 2022. The Department of Defence of the United States provided funding for this trial.
Market Opportunities and Challenges
The market for cancer vaccines is expanding as a result of a number of causes, including an increase in cancer diagnoses, rising government financing for the research of cancer vaccines, and technological advancements in the field. According to the recently released GLOBOCAN 2020 report from the International Agency for Research on Cancer, which estimated the incidence and mortality of 36 cancers in 185 countries worldwide, there were predicted to be 19,292,789 new cases of cancer diagnosed in 2020 and roughly 9,958,133 people worldwide passed away from cancer.
Cancer vaccines are generally expensive due to the extensive research and expenditure required for their production. The high cost of cancer vaccination may prevent patients from seeking treatment in economically depressed or disadvantaged areas. The expense may also discourage healthcare providers from providing immunization services at their facilities. As a result, the expense of the cancer vaccination operates primarily as a barrier to market expansion.
Market Competitive Landscape
The cancer vaccine industry is highly consolidated, with only a few big players. Partnerships, agreements, collaborations, mergers, and acquisitions are some of the growth methods used by market participants to increase their market position. The cancer vaccine industry is dominated by companies such as AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline, Roche.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Technology, By Type, By Indication, By End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, Dendreon, GlaxoSmithKline, Onco Thyreon, Oncovir, Oxford BioMedical, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech. |
COVID-19 Impact on Global Cancer Vaccines Market
COVID-19 has had a limited impact on the Global Cancer Vaccines Market production and distribution firms, owing to shutdowns in various COVID-19 affected nations and an increase in the number of healthcare professionals becoming ill as a result of the pandemic, resulting in low supply. Due to shutdowns in numerous COVID-19-affected countries, the pandemic has impeded cancer vaccine production as well as the import and export of raw materials and finished items. The pandemic also propelled the market, owing to higher product approvals in emerging markets and leading industry players' increased attention on clinical research for the development of new vaccines.
Key Target Audience:
- Biopharmaceutical Companies
- Clinical Researchers and Oncologists
- Regulatory Authorities
- Healthcare Providers
- Patients and Caregivers
- Investors and Funding Organizations
- Academic and Research Institutions
- Pharmaceutical Distributors and Suppliers
- Cancer Advocacy Groups
Our in-depth analysis of the Cancer Vaccines Market includes the following segments:
| By Type: |
|
| By Indication: |
|
| By End User: |
|
Key Topics Covered in the Report:
- Global Cancer Vaccines Market Size (FY’2023-FY’2033)
- Overview of Global Cancer Vaccines Market
- Segmentation of Global Cancer Vaccines Market By Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines.)
- Segmentation of Global Cancer Vaccines Market By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines.)
- Segmentation of Global Cancer Vaccines Market By Indication (Cervical Cancer, Prostate Cancer Others.)
- Segmentation of Global Cancer Vaccines Market By End User (Pediatrics, Adults.)
- Statistical Snap of Global Cancer Vaccines Market
- Expansion Analysis of Global Cancer Vaccines Market
- Problems and Obstacles in Global Cancer Vaccines Market
- Competitive Landscape in the Global Cancer Vaccines Market
- Impact of COVID-19 and Demonetization on Global Cancer Vaccines Market
- Details on Current Investment in Global Cancer Vaccines Market
- Competitive Analysis of Global Cancer Vaccines Market
- Prominent Players in the Global Cancer Vaccines Market
- SWOT Analysis of Global Cancer Vaccines Market
- Global Cancer Vaccines Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data2.1.2 Primary data2.1.3 SPER’s internal database2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers4.1.2 Restraints4.1.3 Opportunities4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Cancer Vaccines Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths5.1.2 Weaknesses5.1.3 Opportunities5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape5.2.2 Economic landscape5.2.3 Social landscape5.2.4 Technological landscape5.2.5 Environmental landscape5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers5.3.2 Bargaining power of Buyers5.3.3 Threat of Substitute5.3.4 Threat of new entrant5.3.5 Competitive rivalry
5.4.Heat map analysis
6. Global Cancer Vaccines Market, By Technology, 2019-2032 (USD Million)
6.1. Antigen/Adjuvant Cancer Vaccines6.2. Dendritic Cells (DC) Cancer Vaccines6.3. Recombinant Cancer Vaccines6.4. Viral Vector & DNA Cancer Vaccines
7. Global Cancer Vaccines Market, By Type, 2019-2032 (USD Million)
7.1. Preventive Cancer Vaccines7.2. Therapeutic Cancer Vaccines
8. Global Cancer Vaccines Market, By Indication, 2019-2032 (USD Million)
8.1. Cervical Cancer8.2. Prostate Cancer8.3. Others.
9. Global Cancer Vaccines Market, By End User, 2019-2032 (USD Million)
9.1. Pediatrics9.2. Adults
10. Global Cancer Vaccines Market, By Region, 2019-2032 (USD Million)
10.1. North America
10.1.1. Canada10.1.2. Mexico10.1.3. United States
10.2. Europe
10.2.1. France10.2.2. Germany10.2.3. Italy10.2.4. Rest of Europe10.2.5. Spain10.2.6. United Kingdom
10.3. Asia-Pacific
10.3.1. Australia10.3.2. China10.3.3. India10.3.4. Japan10.3.5. Rest of Asia-Pacific10.3.6. South Korea
10.4. South America
10.4.1. Brazil10.4.2. Argentina10.4.3. Rest of South America
10.5. Middle East & Africa
10.5.1. Kingdom of Saudi Arabia10.5.2. United Arab Emirates10.5.3. Rest of Middle East & Africa
11. Company Profiles
11.1. Aduro Biotech
11.1.1. Company details11.1.2. Financial outlook11.1.3. Product summary11.1.4. Recent developments
11.2. Advantagene
11.2.1. Company details11.2.2. Financial outlook11.2.3. Product summary11.2.4. Recent developments
11.3. Advaxis
11.3.1. Company details11.3.2. Financial outlook11.3.3. Product summary11.3.4. Recent developments
11.4. Agenus
11.4.1. Company details11.4.2. Financial outlook11.4.3. Product summary11.4.4. Recent developments
11.5. Altor BioScience
11.5.1. Company details11.5.2. Financial outlook11.5.3. Product summary11.5.4. Recent developments
11.6. Argos Therapeutics
11.6.1. Company details11.6.2. Financial outlook11.6.3. Product summary11.6.4. Recent developments
11.7. Dendreon
11.7.1. Company details11.7.2. Financial outlook11.7.3. Product summary
11.7.4. Recent developments
11.8. GlaxoSmithKline
11.8.1. Company details11.8.2. Financial outlook11.8.3. Product summary11.8.4. Recent developments
11.9. OncoThyreon
11.9.1. Company details11.9.2. Financial outlook11.9.3. Product summary11.9.4. Recent developments
11.10. Oncovir
11.10.1. Company details11.10.2. Financial outlook11.10.3. Product summary11.10.4. Recent developments
11.11. Oxford BioMedical
11.11.1. Company details11.11.2. Financial outlook11.11.3. Product summary11.11.4. Recent developments
11.12. Prsima BioMed
11.12.1. Company details11.12.2. Financial outlook11.12.3. Product summary11.12.4. Recent developments
11.13. Sotio
11.13.1. Company details11.13.2. Financial outlook11.13.3. Product summary11.13.4. Recent developments
11.14. Transgene
11.14.1. Company details11.14.2. Financial outlook11.14.3. Product summary11.14.4. Recent developments
11.15. Ubivac
11.15.1. Company details11.15.2. Financial outlook11.15.3. Product summary11.15.4. Recent developments
11.16. Vaccinogen
11.16.1. Company details11.16.2. Financial outlook11.16.3. Product summary11.16.4. Recent developments
11.17. Vaxon Biotech
11.17.1. Company details11.17.2. Financial outlook11.17.3. Product summary11.17.4. Recent developments
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
The Cancer Vaccines Market is projected to reach USD 20.09 billion by 2032, growing at a CAGR of 12.82% during the forecast period.
The Cancer Vaccines Market grew in market size from 2021. The Market is expected to reach USD 20.09 billion by 2032, at a CAGR of 12.82% during the forecast period.
The Cancer Vaccines Market CAGR of 12.82% during the forecast period.
You can get the sample pages by clicking the link -Click Here
The Cancer Vaccines Market size is USD 20.09 billion from 2022 to 2032.
The Cancer Vaccines Market segment is Covered By Technology, By Type, By Indication, By End User.
The North America and Europe region is anticipated to have the highest market share in the Cancer Vaccines Market.
The key players in the market include Companies Covered Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, Dendreon, GlaxoSmithKline, Onco Thyreon, Oncovir, Oxford BioMedical, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech.
Cancer vaccines are classified as biological response modifiers. These modifiers function by activating the immune system to combat illness. Broadly, cancer vaccines are of two types: prevention vaccines and treatment vaccines. In order to prevent cancer, healthy people are given preventive cancer vaccinations.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
